Flexion Therapeutics (FLXN)

Flexion Therapeutics (FLXN) is a specialty pharmaceutical company developing an anti-inflammatory and analgesic injection for the treatment of patients with osteoarthritic pain. FLXN’s lead candidate currently in phase 3 trials is FX006, a sustained-release intra-articular steroid (triamcinolone acetonide) for patients with moderate to severe osteoarthritis (OA) pain.